Follow the people · Insider
Rahsaan Thompson
Rahsaan Thompson files insider transactions with the SEC as a chief legal & compliance of Zevra Therapeutics (ZVRA). We hold 4 disclosed purchases and sales filed since 15 May 2020, 2 of them in the last 90 days.
- Files forZVRA
- Disclosed buys and sells4 in all, 2 in the last 90 days
- Last disclosure17 August 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 21 June 2024 — 14 August 2026Chief Legal & Compliance · Zevra Therapeutics (ZVRA)21 Form 4 lines · source: SEC Form 4
- Filed 10 October 2022 — 24 February 2023Chief Legal Officer · Lyell Immunopharma (LYEL)2 Form 4 lines · source: SEC Form 4
- Filed 13 May 2020 — 31 January 2022EVP and General Counsel · Gritstone bio (GRTS)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
28 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 42,666 shares of Zevra TherapeuticsSEC Form 417 August 2026Common Stock · traded 14 August 2026 · filed 17 August 2026
- exercised options over 66,667 shares of Zevra TherapeuticsSEC Form 423 June 2026Common Stock · traded 21 June 2026 · filed 23 June 2026
- ▼ sold on the open market 34,557 shares of Zevra TherapeuticsSEC Form 423 June 2026Common Stock · traded 22 June 2026 · filed 23 June 2026
- exercised options over 66,667 shares of Zevra Therapeutics (a derivative holding)SEC Form 423 June 2026Restricted Stock Unit · traded 21 June 2026 · filed 23 June 2026
- ▼ sold on the open market 1,794 shares of Zevra TherapeuticsSEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- exercised options over 11,333 shares of Zevra TherapeuticsSEC Form 42 February 2026Common Stock · traded 30 January 2026 · filed 2 February 2026
- ▼ sold on the open market 4,080 shares of Zevra TherapeuticsSEC Form 42 February 2026Common Stock · traded 30 January 2026 · filed 2 February 2026
- was granted 37,500 shares of Zevra Therapeutics (a derivative holding)SEC Form 42 February 2026Restricted Stock Unit · traded 29 January 2026 · filed 2 February 2026
- was granted 37,500 shares of Zevra Therapeutics (a derivative holding)SEC Form 42 February 2026Restricted Stock Unit · traded 29 January 2026 · filed 2 February 2026
- was granted 75,000 shares of Zevra Therapeutics (a derivative holding)SEC Form 42 February 2026Stock Option (right to buy) · traded 29 January 2026 · filed 2 February 2026
- exercised options over 11,333 shares of Zevra Therapeutics (a derivative holding)SEC Form 42 February 2026Restricted Stock Unit · traded 30 January 2026 · filed 2 February 2026
- was granted 75,000 shares of Zevra Therapeutics (a derivative holding)SEC Form 42 February 2026Stock Option (right to buy) · traded 29 January 2026 · filed 2 February 2026
- exercised options over 11,333 shares of Zevra Therapeutics (a derivative holding)SEC Form 42 February 2026Restricted Stock Unit · traded 30 January 2026 · filed 2 February 2026
- exercised options over 11,333 shares of Zevra TherapeuticsSEC Form 42 February 2026Common Stock · traded 30 January 2026 · filed 2 February 2026
- ▼ sold on the open market 4,080 shares of Zevra TherapeuticsSEC Form 42 February 2026Common Stock · traded 30 January 2026 · filed 2 February 2026
- ▼ sold on the open market 24,000 shares of Zevra TherapeuticsSEC Form 430 June 2025Common Stock · traded 26 June 2025 · filed 30 June 2025
- exercised options over 66,666 shares of Zevra Therapeutics (a derivative holding)SEC Form 424 June 2025Restricted Stock Unit · traded 21 June 2025 · filed 24 June 2025
- exercised options over 66,666 shares of Zevra TherapeuticsSEC Form 424 June 2025Common Stock · traded 21 June 2025 · filed 24 June 2025
- was granted 68,000 shares of Zevra Therapeutics (a derivative holding)SEC Form 43 February 2025Stock Option (right to buy) · traded 30 January 2025 · filed 3 February 2025
- was granted 34,000 shares of Zevra Therapeutics (a derivative holding)SEC Form 43 February 2025Restricted Stock Unit · traded 30 January 2025 · filed 3 February 2025
- was granted 200,000 shares of Zevra Therapeutics (a derivative holding)SEC Form 425 June 2024Restricted Stock Unit · traded 21 June 2024 · filed 25 June 2024
- was granted 245,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 428 February 2023Option (right to buy) · traded 24 February 2023 · filed 28 February 2023
- was granted 715,000 shares of Lyell Immunopharma (a derivative holding)SEC Form 412 October 2022Option (right to buy) · traded 10 October 2022 · filed 12 October 2022
- was granted 115,440 shares of Gritstone bio (a derivative holding)SEC Form 420 April 2022Stock Option (Right to Buy) · traded 31 January 2022 · filed 20 April 2022
- was granted 19,240 shares of Gritstone bioSEC Form 420 April 2022Common Stock · traded 31 January 2022 · filed 20 April 2022
- was granted 25,500 shares of Gritstone bioSEC Form 419 November 2021Common Stock · traded 7 January 2021 · filed 19 November 2021
- was granted 60,000 shares of Gritstone Oncology (a derivative holding)SEC Form 410 March 2021Stock Option (Right to Buy) · traded 8 March 2021 · filed 10 March 2021
- was granted 85,000 shares of Gritstone Oncology (a derivative holding)SEC Form 415 May 2020Stock Option (Right to Buy) · traded 13 May 2020 · filed 15 May 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.